Rani Therapeutics
RANI
38 hedge funds and large institutions have $2.02M invested in Rani Therapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less funds holding
Funds holding: 39 → 38 (-1)
10.67% less ownership
Funds ownership: 19.24% → 8.57% (-11%)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
39% less capital invested
Capital invested by funds: $3.32M → $2.02M (-$1.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$164K |
| 2 |
HF
HRT Financial
New York
|
+$59K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$55.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$44.3K |
| 5 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
+$36.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.62M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$23.9K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$13K |
| 4 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
-$7.91K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$6.99K |
RANI Hedge Fund Activity: Q3 2025 in Review
38 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q3 2025, worth a combined $2.02M — down 39% from $3.32M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of RANI and 6 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 9 added.
The largest buyer was Citadel Advisors, adding an estimated $164K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.62M sold.
- 38 institutional investors held Rani Therapeutics (RANI) as of Q3 2025, down from 39 in Q2 2025.
- Funds reported $2.02M of Rani Therapeutics stock for Q3 2025, down 39% quarter-over-quarter.
- 6 funds opened new Rani Therapeutics positions in Q3 2025 and 7 closed out, a net change of -1 holder.
- The largest Rani Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $164K added.
- The largest Rani Therapeutics seller in Q3 2025 was Armistice Capital, an estimated $1.62M sold.
Based on aggregated 13F filings for Q3 2025.